Human cytomegalovirus: taking the strain

Wilkinson, Gavin William Grahame ORCID: https://orcid.org/0000-0002-5623-0126, Davison, Andrew J., Tomasec, Peter, Fielding, Ceri Alan ORCID: https://orcid.org/0000-0002-5817-3153, Aicheler, Rebecca, Murrell, Isa, Seirafian, Sepher, Wang, Edward Chung Yern ORCID: https://orcid.org/0000-0002-2243-4964, Weekes, Michael, Lehner, Paul J., Wilkie, Gavin S. and Stanton, Richard James ORCID: https://orcid.org/0000-0002-6799-1182 2015. Human cytomegalovirus: taking the strain. Medical Microbiology and Immunology 204 (3) , pp. 273-284. 10.1007/s00430-015-0411-4

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

In celebrating the 60th anniversary of the first isolation of human cytomegalovirus (HCMV), we reflect on the merits and limitations of the viral strains currently being used to develop urgently needed treatments. HCMV research has been dependent for decades on the high-passage strains AD169 and Towne, heavily exploiting their capacity to replicate efficiently in fibroblasts. However, the genetic integrity of these strains is so severely compromised that great caution needs to be exercised when considering their past and future use. It is now evident that wild-type HCMV strains are not readily propagated in vitro. HCMV mutants are rapidly selected during isolation in fibroblasts, reproducibly affecting gene RL13, the UL128 locus (which includes genes UL128, UL130 and UL131A) and often the UL/b′ region. As a result, the virus becomes less cell associated, altered in tropism and less pathogenic. This problem is not restricted to high-passage strains, as even low-passage strains can harbour biologically significant mutations. Cloning and manipulation of the HCMV genome as a bacterial artificial chromosome (BAC) offers a means of working with stable, genetically defined strains. To this end, the low-passage strain Merlin genome was cloned as a BAC and sequentially repaired to match the viral sequence in the original clinical sample from which Merlin was derived. Restoration of UL128L to wild type was detrimental to growth in fibroblasts, whereas restoration of RL13 impaired growth in all cell types tested. Stable propagation of phenotypically wild-type virus could be achieved only by placing both regions under conditional expression. In addition to the development of these tools, the Merlin transcriptome and proteome have been characterized in unparalleled detail. Although Merlin may be representative of the clinical agent, high-throughput whole-genome deep sequencing studies have highlighted the remarkable high level of interstrain variation present in circulating virus. There is a need to develop systems capable of addressing the significance of this diversity, free from the confounding effects of genetic changes associated with in vitro adaptation. The generation of a set of BAC clones, each containing the genome of a different HCMV strain repaired to match the sequence in the clinical sample, would provide a pathway to address the biological and clinical effects of natural variation in wild-type HCMV.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology
Publisher:	Springer
ISSN:	0300-8584
Funders:	Wellcome Trust
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	30 March 2015
Last Modified:	11 Oct 2023 20:53
URI:	https://orca.cardiff.ac.uk/id/eprint/73914

Citation Data

Cited 83 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item